Table 2 Distribution of SNPs in OSMR among patients and controls and their association with bladder cancer risk
From: The role of oncostatin M receptor gene polymorphisms in bladder cancer
Model | Â | rs2278329 | Â | rs2292016 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Genotype | Controls | Patients | OR (95% CI) | P value | Genotype | Controls | Patients | OR (95% CI) | P value | |
N = 459 (%) | N = 306 (%) | N = 459 (%) | N = 306 (%) | |||||||
Codominant | GG | 207 (45.1) | 133 (43.5) | 1.00 (reference) | 0.88 | GG | 191 (41.6) | 136 (44.4%) | 1.00 (reference) | 0.70 |
GA | 200 (43.6) | 139 (45.4) | 0.92 (0.68–1.26) | GT | 209 (45.5) | 135 (44.1) | 1.10 (0.81–1.50) | |||
AA | 52 (11.3) | 34 (11.1%) | 1.23 (0.79–1.89) | TT | 59 (12.8) | 35 (11.4) | 1.20 (0.75–1.93) | |||
Dominant | GG | 207 (45.1) | 133 (43.5) | 1.00 (reference) | 0.66 | GG | 191 (41.6) | 136 (44.4) | 1.00 (reference) | 0.44 |
GA/AA | 252 (54.9) | 173 (56.5) | 0.94 (0.70–1.25) | GT/TT | 268 (58.4) | 170 (55.6) | 1.12 (0.84–1.50) | |||
Recessive | GG/GA | 407 (88.7) | 272 (88.9%) | 1.00 (reference) | 0.93 | GG/GT | 400 (87.2) | 271 (88.6) | 1.00 (reference) | 0.56 |
AA | 52 (11.3) | 34 (11.1%) | 1.02 (0.65–1.62) | TT | 59 (12.8) | 35 (11.4) | 1.14 (0.73–1.78) | |||
Overdominant | GG/AA | 259 (56.4) | 167 (54.6%) | 1.00 (reference) | 0.61 | GG/TT | 250 (54.5) | 171 (55.9) | 1.00 (reference) | 0.70 |
GA | 139 (45.4) | 139 (45.4%) | 0.93 (0.69–1.24) | GT | 209 (45.5) | 135 (44.1) | 1.06 (0.79–1.42) | |||
Allele | ||||||||||
G | 614 (66.9) | 405 (66.2) | 0.97 (0.78–1.20) | 0.77 | G | 591 (64.4) | 407 (66.5) | 1.20 (0.84–1.70) | 0.39 | |
A | 304 (33.1) | 207 (33.8) | T | 327 (35.6) | 205 (33.5) | |||||